Gate2Brain will be attending RESI JMP San Francisco 2025
Gate2Brain will be in San Francisco during JPM2025, from the 13th and 17th January 2025. Pitching at #RESIJPM 2025 on the 14th of January 2025.
Gate2Brain, a cutting-edge technology platform dedicated to overcoming biological barriers—including the blood-brain barrier—has achieved a significant milestone in the fight against brain tumors for its first innovative product, G2B-002. The European Medicines Agency (EMA) has recently granted Orphan Drug Designation (ODD) and now we are starting our path within FDA.
Join us in our transformative Series A funding round, currently in design and supported by a 50% co-investment from the European Innovation Council and SMEs Executive Agency (EISMEA) EIC Accelerator.
This is your chance to contribute to scaling a breakthrough technology poised to redefine therapeutic delivery across biological barriers, enabling innovative brain delivery solutions and achieving our shared goal of bringing these groundbreaking products to patients.
Be sure to join us to learn more about Gate2Brain’s novel technology for the delivery of therapeutics across biological barriers. A platform technology ready for R&D and out-licensing agreements.
Gate2Brain as a finalist at the INNOVATOR’S PITCH CHALLENGE will be presenting its technology to a panel in the category of “Novel Drug Delivery”. The session will take place at the Marriott Marquis San Francisco (780 Mission St. San Francisco, CA 94103), on Tuesday, January 14, 9:00 – 10:00 am, at the Golden Gate C3 room.
🌐 More information about G2B: https://gate2brain.com
Join us for a one-to-one meeting
Don’t hesitate to contact us to set a Face-to-Face meeting between the 13 and 17th January at
📧meritxell.teixido@gate2brain.com, (CEO / CSO)
📧 carles.taule@gate2brain.com (Business Development Manager)
